List of Excipients in Branded Drug GABITRIL

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	GABITRIL	tiagabine hydrochloride	16590-832	ASCORBIC ACID
STAT RX USA LLC	GABITRIL	tiagabine hydrochloride	16590-832	CELLULOSE, MICROCRYSTALLINE
STAT RX USA LLC	GABITRIL	tiagabine hydrochloride	16590-832	CROSPOVIDONE

Gabitril Excipient Strategy and Commercial Opportunities for Tiagabine

Last updated: August 22, 2026

Gabitril is an immediate-release tiagabine hydrochloride tablet approved for adjunctive treatment of partial seizures in patients aged 12 years and older. Its original formulation uses conventional tablet excipients, and the principal commercial opportunity is a low-cost generic or differentiated oral solid dosage form rather than a patent-protected reformulation. The strongest opportunities are lactose-free tablets, improved swallowability, pediatric liquid or dispersible products, and manufacturing-cost reductions that preserve bioequivalence.

What is Gabitril and how is it regulated?

Gabitril contains tiagabine hydrochloride, a selective gamma-aminobutyric acid reuptake inhibitor. The U.S. Food and Drug Administration approved Gabitril under NDA 020646 for adjunctive therapy in partial seizures.[1]

Attribute	Gabitril profile
Active ingredient	Tiagabine hydrochloride
Brand	Gabitril
Original sponsor	Cephalon
Current commercial affiliation	Cephalon assets were acquired by Teva
Dosage form	Immediate-release oral tablets
Strengths	2 mg, 4 mg and 12 mg
FDA indication	Adjunctive treatment of partial seizures
Original patient population	Adults and children aged 12 years and older
Pharmacologic class	Anticonvulsant
FDA pathway for generics	ANDA, subject to reference-product requirements
Biosimilar pathway	Not applicable; tiagabine is a small molecule

Gabitril is not a biologic, so biosimilar competition does not apply. Competition is expected through abbreviated new drug applications, authorized generic arrangements, and potentially 505(b)(2) products with altered dosage forms or delivery systems.

What excipients are used in Gabitril tablets?

The Gabitril label identifies conventional excipients used in immediate-release tablets. Public labeling identifies materials including lactose monohydrate, microcrystalline cellulose, pregelatinized starch, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, talc and strength-specific colorants.[1]

The excipient system performs four primary functions:

1. Lactose and microcrystalline cellulose provide tablet bulk.
2. Pregelatinized starch supports compressibility and disintegration.
3. Hydroxypropyl cellulose acts as a binder.
4. Colloidal silicon dioxide and magnesium stearate support flow and lubrication.
5. Hypromellose, talc, titanium dioxide and colorants form and standardize the film coating.

The precise quantitative formula is proprietary and may vary by manufacturing site or post-approval supplement. Generic developers should treat the public inactive-ingredient listing as a screening reference, not as a complete reverse-engineering specification.

Which excipient strategies offer the best commercial opportunities?

Lactose-free Gabitril generic

A lactose-free version is the clearest excipient-led opportunity. Lactose is common in oral solid dosage forms, but some patients avoid it because of intolerance, dietary preference or perceived excipient sensitivity.

Potential replacements include:

• Mannitol for a non-lactose diluent with favorable mouthfeel.
• Dibasic calcium phosphate for density and compressibility.
• Microcrystalline cellulose for dilution and compactibility.
• Copovidone or hydroxypropyl cellulose for binding.
• Crospovidone or sodium starch glycolate for rapid disintegration.

A lactose-free generic can be developed as a standard ANDA if it matches the reference product’s performance and satisfies inactive-ingredient requirements. The commercial advantage is usually modest because the product remains therapeutically substitutable. The opportunity is stronger in hospital formularies, specialty pharmacies and patients who specifically seek lactose-free medicines.

Low-cost direct-compression formulation

Gabitril’s conventional tablet composition provides room for process simplification. A direct-compression formula using microcrystalline cellulose, mannitol or dibasic calcium phosphate, a modern superdisintegrant and a low-level lubricant could reduce granulation, drying and milling steps.

The main technical risks are:

• Content uniformity at the 2 mg strength.
• Segregation caused by differences in particle size or density.
• Over-lubrication and slower dissolution.
• Compression defects at low drug loading.
• Coating weight variation across three strengths.

The 2 mg tablet is likely to present the highest formulation challenge because the amount of active ingredient is small relative to the total tablet mass. A common platform formula across the 2 mg, 4 mg and 12 mg strengths can reduce inventory and validation costs, but the 2 mg strength may require geometric dilution, granulation or a separate blend strategy.

Improved swallowability

Patients with epilepsy may have difficulty swallowing during acute illness, in pediatric use or when multiple medicines are taken together. A smaller tablet, smoother film coat or orally disintegrating tablet could support product differentiation.

An orally disintegrating tiagabine product would require careful control of:

• Taste masking.
• Mechanical strength.
• Disintegration time.
• Moisture sensitivity.
• Dose uniformity.
• Packaging protection.

Tiagabine’s sensory profile and required dose range could make taste masking commercially important. Ion-exchange resins, polymeric coatings, cyclodextrin complexes and multiparticulate coating technologies are possible approaches, but each can affect dissolution and bioavailability.

A new orally disintegrating product would likely require a more complex regulatory strategy than a conventional ANDA unless the formulation remains within the applicable product and bioequivalence framework.

Pediatric liquid or dispersible product

Gabitril labeling covers patients aged 12 years and older, leaving a limited pediatric opportunity compared with medicines approved for infants or young children. A liquid or dispersible product could still address adolescents, patients with dysphagia and individuals who cannot reliably swallow tablets.

Possible platforms include:

• A ready-to-use aqueous suspension.
• A dry powder for reconstitution.
• A powder sachet dispersed in water.
• A dispersible tablet.
• A multiparticulate formulation administered with soft food.

Tiagabine’s chemical stability, pH-dependent solubility, taste and dose-volume requirements would determine the most viable approach. A liquid product also introduces preservative selection, microbial control, container-closure compatibility and in-use stability requirements.

The commercial case is strongest if the product can be used with a calibrated oral syringe and offers a lower administration burden than splitting or crushing tablets.

What formulation patents could protect a new tiagabine product?

A new formulation could potentially receive patent protection for a specific technical combination rather than for tiagabine itself. The most defensible claim areas would include:

• A defined particle-size distribution.
• A particular amorphous or crystalline form.
• A taste-masked multiparticulate.
• A controlled-release matrix.
• A stable aqueous suspension.
• A moisture-resistant tablet coating.
• A specific excipient ratio that improves dissolution or content uniformity.
• A manufacturing process that produces a defined impurity profile.
• A dispersible dosage form with a defined reconstitution or disintegration profile.

A broad claim covering “tiagabine plus conventional tablet excipients” would face substantial validity risk. Patent strength would depend on unexpected performance, reproducible formulation boundaries and comparative data against the reference product and prior art.

The strongest formulation patent would link the excipient selection to a measurable technical result, such as improved stability under accelerated conditions, faster dissolution across pH ranges, reduced content variability or a clinically relevant administration benefit.

When does Gabitril lose exclusivity?

Gabitril’s original small-molecule exclusivity and core patent protection have expired or are no longer expected to block ordinary generic entry. The product has been on the U.S. market for more than two decades, and tiagabine is commercially positioned as an established anticonvulsant rather than a newly protected branded product.

Exclusivity category	Gabitril assessment
New chemical entity exclusivity	Expired
Original brand patent estate	Historical protection; no meaningful barrier expected for ordinary generic entry
Pediatric exclusivity	Historical period, if granted, has expired
Orphan exclusivity	Not identified as the basis of Gabitril’s principal U.S. approval
Current formulation exclusivity	No established market barrier for a conventional generic
Biosimilar exclusivity	Not applicable
Generic pathway	ANDA for equivalent immediate-release tablets
Differentiated formulation pathway	Potentially 505(b)(2) or full NDA, depending on product and reference strategy

The current Orange Book listing and FDA patent-certification information should control any transaction or launch decision because patents, exclusivity codes and reference-product status can change through supplements or administrative updates.[2]

What is the Orange Book status and Paragraph IV risk?

For a conventional tiagabine tablet, the principal launch pathway is an ANDA referencing Gabitril or the applicable reference-listed drug. A Paragraph IV certification becomes relevant only if an applicant challenges a listed patent as invalid, unenforceable or not infringed.

Given the age of Gabitril, a conventional ANDA is more likely to face:

• Product-specific bioequivalence requirements.
• Reference-standard availability issues.
• Low commercial margins.
• Potential competition from existing generic suppliers.
• Limited opportunity to obtain 180-day exclusivity unless a qualifying Paragraph IV filing is made.

A Paragraph IV strategy would have value only if a live Orange Book patent materially delayed entry and the applicant had a commercially meaningful first-filer position. A formulation patent owned by a third party would not automatically create a blocking position unless it is listed against the reference product and remains enforceable.

How strong is the Gabitril patent estate?

The estate is weak for basic immediate-release tiagabine tablets and potentially stronger for a genuinely differentiated delivery system.

Patent category	Relative strength
Tiagabine compound claims	Low for current entry; historical protection
Conventional tablet composition	Low unless a narrow, non-obvious formulation is demonstrated
Lactose-free substitution	Low to moderate; generally vulnerable to obviousness attacks
Orally disintegrating tablet	Moderate if supported by taste, stability and dissolution data
Pediatric liquid	Moderate if stability and palatability are unexpected
Controlled release	Moderate to high technically, but clinical and regulatory burden is greater
Manufacturing process	Moderate if impurity control or yield improvement is unexpected
Device or packaging	Narrow protection with limited blocking power

Excipient selection by itself is rarely a durable moat. The patent value increases when the formulation solves a documented problem that the reference product does not address.

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barrier is not active-ingredient complexity. It is reliable production of low-dose tablets across multiple strengths while maintaining content uniformity and dissolution.

Critical development controls include:

• Tiagabine particle-size distribution.
• Blend homogeneity.
• Order of excipient addition.
• Lubrication time.
• Compression force.
• Film-coating uniformity.
• Residual moisture.
• Stability-indicating analytical methods.
• Packaging performance.

The active ingredient may be sourced from multiple qualified manufacturers, but supply qualification must address impurity profile, polymorphic form, residual solvents and particle engineering. A supplier with a lower active-ingredient price may create downstream costs if the material produces poor blend uniformity or slower dissolution.

A differentiated product can build intellectual-property protection around process control, packaging, particle engineering and dosage-form performance. Those rights are more likely to support premium pricing than a simple lactose-free substitution.

How does Gabitril compare with competing anticonvulsant opportunities?

Gabitril has a smaller commercial market than high-volume generic anticonvulsants such as levetiracetam, lamotrigine, gabapentin and topiramate. Its commercial advantages are a limited number of strengths, a conventional tablet platform and an established regulatory history. Its disadvantages are a narrower indication, lower likely market volume and the absence of meaningful brand exclusivity.

Product strategy	Development cost	Regulatory complexity	Pricing potential	Market risk
Conventional generic tablet	Low to moderate	Low	Low	High
Lactose-free tablet	Low to moderate	Low to moderate	Low to moderate	Moderate
Smaller or coated tablet	Moderate	Moderate	Moderate	Moderate
Oral suspension	Moderate	Moderate	Moderate	Moderate
Orally disintegrating tablet	Moderate to high	Moderate to high	Moderate	Moderate to high
Controlled-release product	High	High	Higher if clinically differentiated	High

For a contract manufacturer or generic company, the best risk-adjusted opportunity is usually a conventional ANDA with a simplified, lactose-free or cost-optimized formulation. For a specialty pharmaceutical company, an oral liquid or dispersible formulation offers greater differentiation but requires more evidence and commercial investment.

What licensing deals and commercial partnerships are relevant?

The original Gabitril rights were associated with Cephalon, which was acquired by Teva in 2011.[3] The product’s commercial history makes a conventional branded licensing deal less attractive than:

• An ANDA asset sale.
• A private-label supply agreement.
• A regional commercialization license.
• A formulation-development partnership.
• A contract manufacturing arrangement.
• An authorized generic transaction.
• A specialty-pharmacy distribution agreement.

The value of a licensing deal would depend on formulation differentiation, regulatory status, supply reliability and access to the reference product for bioequivalence work. A plain generic tablet is unlikely to command significant upfront consideration unless it has an approved ANDA, scarce manufacturing capacity or a defensible market-access position.

What generic launch scenarios exist for Gabitril?

Immediate launch after ANDA approval

This is the lowest-risk technical scenario but also the most competitive. Multiple suppliers can enter a mature anticonvulsant market, leading to rapid price erosion.

First-filer Paragraph IV launch

This scenario has value only if a current listed patent exists and the applicant secures the relevant exclusivity position. Historical Gabitril patent protection does not, by itself, create a current first-filer opportunity.

Differentiated tablet launch

A lactose-free, smaller or more swallowable tablet could support modest price differentiation. Substitution rules and payer policies would limit the premium.

Liquid or dispersible launch

A liquid, powder or dispersible tablet could target patients with swallowing difficulty and provide a specialty product position. The product would face additional stability, palatability and adherence-development requirements.

Authorized generic or private-label launch

This route can provide a lower-risk commercial entry if supply, manufacturing and distribution rights are available. The principal risks are low margins and dependence on the brand owner or upstream supplier.

Key Takeaways

• Gabitril is an established tiagabine hydrochloride immediate-release tablet with no biosimilar pathway.
• Conventional generic entry is primarily an ANDA opportunity.
• Lactose-free reformulation is the most practical excipient-led differentiation.
• The 2 mg strength creates the greatest content-uniformity and blend-segregation risk.
• Oral liquid, dispersible and orally disintegrating products offer stronger differentiation but require greater regulatory work.
• Excipient claims alone are unlikely to create a durable patent barrier.
• A defensible formulation patent should rely on defined composition limits and unexpected technical performance.
• The commercial market is mature, narrow and price-sensitive.
• The best risk-adjusted strategy is a low-cost, lactose-free, bioequivalent tablet supported by efficient manufacturing and reliable supply.
• A specialty formulation is more attractive where the sponsor can demonstrate a meaningful administration benefit.

FAQs About Gabitril Excipient and Formulation Opportunities

Can Gabitril tablets be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, microcrystalline cellulose, dibasic calcium phosphate or another suitable diluent, subject to tablet performance, inactive-ingredient limits and bioequivalence requirements.

Is tiagabine suitable for an orally disintegrating tablet?

Potentially. The main development issues are taste masking, dose uniformity, mechanical strength, moisture protection and dissolution equivalence.

Does Gabitril have biosimilar competition?

No. Tiagabine is a chemically synthesized small molecule, so competition proceeds through generic-drug pathways rather than biosimilar regulation.

What is the most valuable Gabitril formulation patent opportunity?

A patent covering a stable, palatable liquid or dispersible formulation with demonstrated technical advantages is likely to have greater commercial value than a broad patent covering routine tablet excipient substitutions.

Is a generic Gabitril launch commercially attractive?

It can be attractive for a manufacturer with low-cost tiagabine supply, efficient tablet production and established distribution. Returns are likely to be limited for an undifferentiated product because the market is mature and price competition can be intense.

References

1. U.S. Food and Drug Administration. (2012). Gabitril (tiagabine hydrochloride) tablets prescribing information. Cephalon, Inc.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Teva Pharmaceutical Industries Ltd. (2011). Teva completes acquisition of Cephalon. https://www.tevapharm.com/news-and-media/press-releases/